公司資料
AIM ImmunoTech 股價、新聞與催化劑
- 股票代碼:
- AIM
- 交易所:
- AMEX
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.25 USD (-1.70%)
收盤價
最後更新: 2026年8月24日
12M USD
市值
股價為何變動
As of Aug 24, 2026, AIM closed down 1.70% at $0.2540. No new same-company headline was identified in the current news window.
公司概覽
Immunomodulator Development
AIM ImmunoTech is an immuno-pharma company developing Ampligen for oncology and selected infectious-disease applications. Its primary strategic focus is late-stage pancreatic cancer.
Ampligen
Ampligen, or rintatolimod, is a double-stranded RNA immunomodulator and selective TLR3 agonist. The candidate is designed to activate innate immune pathways and has been evaluated across multiple cancers, viral diseases and immune-related conditions.
Pancreatic Cancer Program
The Phase 2 DURIPANC study evaluates Ampligen with the anti-PD-L1 therapy durvalumab in metastatic pancreatic cancer. AIM is using the study and prior named-patient survival experience to inform the design of a planned pivotal Phase 3 program.
未來催化劑
- DURIPANC Phase 2 clinical-benefit data in the first quarter of 2027.
- DURIPANC Phase 2 overall-survival data in the third quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。